more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Research Report
  ()
The company's flagship gene therapy posted a fifth consecutive sequential decline in 2Q26, with DM1 and FSHD data updates seen as the next potential value inflection points.
Tags: Biotechnology / Pharmaceuticals

Virtual Care Network Expands to Include 100,000 More New Yorkers, Reaching 24 Million Nationwide

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) recently added 100,000 eligible members in New York to its network. This expansion brings the total number of individuals with potential in-network access to the company's virtual care services to approximately 10 million in New York and 24 million across the United States.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Virtual Care AI Provider Expands Potential Access to 100k+ New York Covered Lives

  ()
Rocket Doctor AI expanded potential in-network access to more than 100,000 additional eligible covered lives in New York through a new payer agreement, while continuing to expand its physician network and healthcare AI capabilities in the United States.
Tags: Biotechnology / PharmaceuticalsHealthcare ServicesArtificial Intelligence

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

  ()
Sarepta Therapeutics contends with an FDA clinical hold on Elevidys following safety signals, while the Duchenne muscular dystrophy market projects strong growth through 2030.
Tags: Biotechnology / Pharmaceuticals

Myelofibrosis Combo Advances as Karyopharm Preps August sNDA

  ()
Karyopharm Therapeutics plans an sNDA filing for selinexor plus ruxolitinib in myelofibrosis. SVR35 endpoint and Phase 3 SENTRY data support the accelerated approval path.
Tags: Biotechnology / Pharmaceuticals

Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial

  ()
Evommune begins Phase 2b testing of oral MRGPRX2 antagonist EVO756 for migraine prevention. The placebo-controlled study targets 330 patients with doses up to 100 mg and reports data in 2027.
Tags: Biotechnology / Pharmaceuticals

New GLP-1 Platform Combines Doctor Prescriptions, AI Coaching and Chronic Care

  ()
DarioHealth Corp. (NASDAQ: DRIO) introduced its Integrated GLP-1 Program, bringing licensed provider evaluations, FDA-approved GLP-1 prescribing where clinically appropriate and ongoing care into one experience.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Digital Health Firm Launches Integrated GLP-1 Program

  ()
DarioHealth integrates its digital platform with licensed providers to offer end-to-end GLP-1 support. See how the new program targets employers and health plans in a growing market.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Sarepta Grants New CEO 2.2M Stock Options Amid "Sell" Rating

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring.
Tags: Biotechnology / Pharmaceuticals

Karyopharm Pursues Myelofibrosis FDA Milestone

  ()
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis.
Tags: Biotechnology / Pharmaceuticals

Evommune Doses First Patient in Migraine Trial

  ()
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor.
Tags: Biotechnology / Pharmaceuticals

Biotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifies

  ()
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move.
Tags: Biotechnology / Pharmaceuticals

Dyadic C1 Platform Delivers Ebola Antigens in 15 Days

  ()
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa.
Tags: Biotechnology / Pharmaceuticals

Wet AMD Drug Secures First FDA-Approved Bevacizumab Status

  ()
Outlook Therapeutics gains FDA approval for LYTENAVA, the first ophthalmic bevacizumab for wet AMD. The approval opens access to an $8.5 billion U.S. market with 12 years of exclusivity expected.
Tags: Biotechnology / Pharmaceuticals

Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer

Contributed Opinion
  ()
Newsletter writer Chen Lin shares his view on the current state of the market and shares some stocks on his list.
Tags: GoldBiotechnology / PharmaceuticalsTechnologyCopperSilver

Scancell, Neuphoria Agree to All-Share Merger

  ()
Neuphoria Therapeutics Inc. (NEUP:NASDAQ) and Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) agreed to an all-share merger, listing the combined company on Nasdaq while funding a Phase 3 melanoma trial.
Tags: Biotechnology / Pharmaceuticals

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

  ()
Scancell advances its iSCIB1+ melanoma program toward Phase 3 after agreeing to an all-share merger that brings Nasdaq access and up to $89 million in new financing.
Tags: Biotechnology / Pharmaceuticals

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target

  ()
Outlook Therapeutics Inc.'s (OTLK:NASDAQ) LYTENAVA received FDA approval as the first ophthalmic bevacizumab for wet AMD, with U.S. launch targeted by year-end 2026
Tags: Biotechnology / Pharmaceuticals

Novocure Posts Record Q2 Revenue of US$183.6M

  ()
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.
Tags: Biotechnology / Pharmaceuticals

Novocure Hits Record Revenue and Raises 2026 Outlook

  ()
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Ashok Kumar Says Commercial Runway Supports Outlook for Health Co.

Research Report
  ()
Visible commercial conversion and improving cash use through the third-quarter report would strengthen the base case and support confidence in the rating and target.
Tags: Biotechnology / Pharmaceuticals

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Research Report
  ()
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
Tags: Biotechnology / Pharmaceuticals

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

  ()
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 121 Next